AQR Capital Management’s DataMeds AI MEDS Stock Holding History

AQR Capital Management’s Portfolio MEDS Stock Details MEDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-406	Closed	-$1.96K	–	3981
2026 Q1	$1.96K	Buy	+406	New	+$5.57K	﹤0.01%	3738

Other funds holding MEDS

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return

GRP

Global Retirement Partners San Rafael, California $6.54B AUM

Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

AQR Capital Management's MEDS Position: Q2 2026 in Review

AQR Capital Management sold out of DataMeds AI (MEDS) in Q2 2026, closing a stake of 406 shares — an estimated $1.96K sold.

AQR Capital Management first reported a position in MEDS in Q1 2026 and held it in 1 quarter. The position peaked at $1.96K in Q1 2026. 9 funds tracked by Wall St. Rank hold MEDS as of Q2 2026.

AQR Capital Management reported no remaining DataMeds AI position as of Q2 2026 after selling out during the quarter.
AQR Capital Management sold 406 DataMeds AI shares in Q2 2026, an estimated $1.96K.
AQR Capital Management first reported a position in DataMeds AI in Q1 2026 and held it in 1 quarter.
AQR Capital Management's DataMeds AI position peaked at $1.96K in Q1 2026.
9 funds tracked by Wall St. Rank held DataMeds AI as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.